Company Profile
MiNK Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- INKT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
10.59 USD (-4.34%)
Close
Last updated: July 27, 2026
59.6M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, INKT closed down 4.34% at $10.59. No new same-company headline was identified in the current news window.
Company overview
Business overview
MiNK Therapeutics is a cell-therapy company focused on invariant natural killer T-cell biology and immune-oncology. Its story is built around an unusual immune-cell platform that aims to create broad anti-tumor activity.
Geographic Base and Sector Classification
MiNK Therapeutics is headquartered in the United States and listed on NASDAQ. It sits in cell therapy and oncology biotechnology.
Business Model Characteristics
The company depends on translational and clinical validation, manufacturing feasibility, and capital support. Investors usually watch early data, safety, and platform differentiation.
Position Within the Biotechnology Landscape
MiNK occupies a specialized cell-therapy niche within biotech. It remains highly catalyst-sensitive because the platform is still proving itself in the clinic.
Future catalysts
MiNK Therapeutics’ catalysts are invariant NK-cell programs and any clinical update that shows the platform can still produce differentiating data. The company remains early and data-dependent.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MiNK Therapeutics, Inc. (INKT)?
MiNK Therapeutics, Inc. (INKT) most recently closed at 10.59 USD, a -4.34% move versus the previous session.
What is the market cap of MiNK Therapeutics, Inc. (INKT)?
MiNK Therapeutics, Inc. currently has a market capitalization of 59.6M USD on BioPharmSignal.
What does MiNK Therapeutics, Inc. do?
MiNK Therapeutics is a cell-therapy company focused on invariant natural killer T-cell biology and immune-oncology. Its story is built around an unusual immune-cell platform that aims to create broad anti-tumor activity.
On which exchange is INKT stock listed?
MiNK Therapeutics, Inc. (INKT) is associated with NASDAQ, United States, Biopharma.
What is MiNK?
MiNK Therapeutics’ catalysts are invariant NK-cell programs and any clinical update that shows the platform can still produce differentiating data.
Which conditions is MiNK Therapeutics, Inc. targeting with MiNK?
MiNK Therapeutics, Inc. is associated with oncology based on its company overview and current catalyst commentary.
How does MiNK Therapeutics, Inc. describe recent progress with MiNK?
MiNK Therapeutics’ catalysts are invariant NK-cell programs and any clinical update that shows the platform can still produce differentiating data.
What is Therapeutics?
MiNK Therapeutics is a cell-therapy company focused on invariant natural killer T-cell biology and immune-oncology.